 10. In treatment with immune modulating products 3 months prior to inclusion or during the trial, e.g. blood products, immunoglobulins, cytostatics e.g. methotrexate, TNF-antagonists e.g. etanercerpt, infliximab, adalimumab, golimumab, certolizumab, or immunosuppressants e.g. azathioprine or ciclosporin 